These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

380 related articles for article (PubMed ID: 22531234)

  • 101. Outcome of the Respiratory Syncytial Virus related acute lower respiratory tract infection among hospitalized newborns: a prospective multicenter study.
    Alan S; Erdeve O; Cakir U; Akduman H; Zenciroglu A; Akcakus M; Tunc T; Gokmen Z; Ates C; Atasay B; Arsan S;
    J Matern Fetal Neonatal Med; 2016; 29(13):2186-93. PubMed ID: 26365531
    [TBL] [Abstract][Full Text] [Related]  

  • 102. Motavizumab treatment of infants hospitalized with respiratory syncytial virus infection does not decrease viral load or severity of illness.
    Ramilo O; Lagos R; Sáez-Llorens X; Suzich J; Wang CK; Jensen KM; Harris BS; Losonsky GA; Griffin MP;
    Pediatr Infect Dis J; 2014 Jul; 33(7):703-9. PubMed ID: 24356256
    [TBL] [Abstract][Full Text] [Related]  

  • 103. A meta-analysis of the effect of antibody therapy for the prevention of severe respiratory syncytial virus infection.
    Morris SK; Dzolganovski B; Beyene J; Sung L
    BMC Infect Dis; 2009 Jul; 9():106. PubMed ID: 19575815
    [TBL] [Abstract][Full Text] [Related]  

  • 104. Impact of the Withdrawal of Palivizumab Immunoprophylaxis on the Incidence of Respiratory Syncytial Virus (RSV) Hospitalizations Among Infants Born at 33 to 35 Weeks' Gestational Age in the Province of Quebec, Canada: The RSV-Quebec Study.
    Papenburg J; Defoy I; Massé E; Caouette G; Lebel MH
    J Pediatric Infect Dis Soc; 2021 Apr; 10(3):237-244. PubMed ID: 32530035
    [TBL] [Abstract][Full Text] [Related]  

  • 105. Systematic Review of the Safety and Efficacy of Palivizumab among Infants and Young Children with Cystic Fibrosis.
    Kua KP; Lee SWH
    Pharmacotherapy; 2017 Jun; 37(6):755-769. PubMed ID: 28423192
    [TBL] [Abstract][Full Text] [Related]  

  • 106. Healthy Late-preterm infants born 33-36+6 weeks gestational age have higher risk for respiratory syncytial virus hospitalization.
    Helfrich AM; Nylund CM; Eberly MD; Eide MB; Stagliano DR
    Early Hum Dev; 2015 Sep; 91(9):541-6. PubMed ID: 26186560
    [TBL] [Abstract][Full Text] [Related]  

  • 107. Hospitalization for respiratory syncytial virus illness in Down syndrome following prophylaxis with palivizumab.
    Paes B; Mitchell I; Yi H; Li A; Lanctôt KL;
    Pediatr Infect Dis J; 2014 Feb; 33(2):e29-33. PubMed ID: 23989104
    [TBL] [Abstract][Full Text] [Related]  

  • 108. Infants born before 32 weeks of gestation or with respiratory disease are most likely to receive palivizumab in the Netherlands.
    Kool-Houweling LM; Penning-van Beest FJ; Bezemer ID; van Lingen RA; Herings RM
    Acta Paediatr; 2015 Sep; 104(9):927-32. PubMed ID: 26073782
    [TBL] [Abstract][Full Text] [Related]  

  • 109. Respiratory hospitalizations and respiratory syncytial virus prophylaxis in special populations.
    Paes B; Mitchell I; Li A; Lanctôt KL
    Eur J Pediatr; 2012 May; 171(5):833-41. PubMed ID: 22203430
    [TBL] [Abstract][Full Text] [Related]  

  • 110. Palivizumab in infants with gestational age < or = 28 weeks and bronchopulmonary dysplasia.
    Parmigiani S; Ubaldi A; Capuano C; Massinissa Magini G; Bianchi ME
    Acta Biomed Ateneo Parmense; 2001; 72(5-6):109-13. PubMed ID: 12233268
    [TBL] [Abstract][Full Text] [Related]  

  • 111. Receipt of palivizumab before birth hospitalization discharge among preterm infants in the United States.
    La Gamma EF; Kumar VR; Wadhawan R; Ye S; Sifakis F; Ycas J; Ambrose CS
    Am J Perinatol; 2015 Sep; 32(11):1017-23. PubMed ID: 25877742
    [TBL] [Abstract][Full Text] [Related]  

  • 112. Adherence to Palivizumab for Respiratory Syncytial Virus Prevention in the Canadian Registry of Palivizumab.
    Chan P; Li A; Paes B; Abraha H; Mitchell I; Lanctôt KL;
    Pediatr Infect Dis J; 2015 Dec; 34(12):e290-7. PubMed ID: 26780032
    [TBL] [Abstract][Full Text] [Related]  

  • 113. SENTINEL1: An Observational Study of Respiratory Syncytial Virus Hospitalizations among U.S. Infants Born at 29 to 35 Weeks' Gestational Age Not Receiving Immunoprophylaxis.
    Anderson EJ; Krilov LR; DeVincenzo JP; Checchia PA; Halasa N; Simões EA; Domachowske JB; Forbes ML; Pannaraj PS; McBride SJ; McLaurin KK; Kumar VR; Ambrose CS
    Am J Perinatol; 2017 Jan; 34(1):51-61. PubMed ID: 27233106
    [No Abstract]   [Full Text] [Related]  

  • 114. Respiratory Syncytial Virus Associated Hospitalizations in Infants of 33 to 42 Weeks' Gestation: Does Gestational Age Matter?
    Resch B; Wörner C; Özdemir S; Hubner M; Puchas C; Urlesberger B
    Klin Padiatr; 2019 Jul; 231(4):206-211. PubMed ID: 30887492
    [TBL] [Abstract][Full Text] [Related]  

  • 115. Palivizumab prophylaxis: does it have any influence on the growth and development of the infants?
    Tavsu I; Gursoy T; Dirman S; Erbil N; Ovali F
    Am J Perinatol; 2014 Sep; 31(8):667-72. PubMed ID: 24022378
    [TBL] [Abstract][Full Text] [Related]  

  • 116. Detection, control, and management of a respiratory syncytial virus outbreak in a pediatric hematology-oncology department.
    Shachor-Meyouhas Y; Zaidman I; Kra-Oz Z; Arad-Cohen N; Kassis I
    J Pediatr Hematol Oncol; 2013 Mar; 35(2):124-8. PubMed ID: 23128340
    [TBL] [Abstract][Full Text] [Related]  

  • 117. RSV prophylaxis use in high-risk infants in Western Australia, 2002-2013: a record linkage cohort study.
    Xu R; Fathima P; Strunk T; de Klerk N; Snelling TL; Richmond PC; Keil AD; Moore HC
    BMC Pediatr; 2020 Oct; 20(1):490. PubMed ID: 33092566
    [TBL] [Abstract][Full Text] [Related]  

  • 118. Respiratory syncytial virus outbreak defined by rapid screening in a neonatal intensive care unit.
    Dizdar EA; Aydemir C; Erdeve O; Sari FN; Oguz S; Uras N; Dilmen U
    J Hosp Infect; 2010 Aug; 75(4):292-4. PubMed ID: 20299133
    [TBL] [Abstract][Full Text] [Related]  

  • 119. Prospective population-based study of RSV-related intermediate care and intensive care unit admissions in Switzerland over a 4-year period (2001-2005).
    Berger TM; Aebi C; Duppenthaler A; Stocker M;
    Infection; 2009 Apr; 37(2):109-16. PubMed ID: 19412586
    [TBL] [Abstract][Full Text] [Related]  

  • 120. Respiratory Syncytial Virus Preterm (32-36 Completed Weeks of Gestation) Risk Estimation Measure for RSV Hospitalization in Ireland: A Prospective Study.
    Sheridan-Pereira M; Murphy J; Sloan J; Crispino G; Leahy A; Corcoran JD; Dempsey E; Elnazir B; Gavin P; Sharif F; Gul R; Satas S; Murphy J; Gormally S; Shanaa I; Waldron D; Mc Mahon P; Carson J; Blanken M; Bont L; Paes B
    Pediatr Infect Dis J; 2016 Jan; 35(1):19-24. PubMed ID: 26379160
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.